



**Food and Drug Administration Advisory Committee Member
Acknowledgment of Financial Interests**

Name of Advisory Committee Member: **John Kirkpatrick, MD**

Committee: **Anesthetic and Analgesic Drug Products Advisory Committee**

Meeting Date: **January 10, 2025**

I acknowledge that contingent upon public disclosure of the following financial interests related to the agenda item described below, I may be considered for participation in the advisory committee meeting.

On January 10, 2025, the Committee will discuss biologics license application (BLA) 761393, condoliase injection submitted by Seikagaku Corporation, for the proposed indication of the treatment of radicular leg pain associated with lumbar disc herniation in adults.

<u>Type of Interest</u>	<u>Nature</u>	<u>Magnitude</u>
I. Personal/Immediate Family		
Stocks/investments	Stock holdings in two competing firms (b) (6)	Aggregate value: \$25,000 – \$50,000
II. Other Imputed Interests		
None		

I hereby request that FDA make this information publicly available on my behalf if the agency grants a waiver allowing me to participate in the meeting described above. I understand that without public disclosure of these interests, I will not participate in the advisory committee meeting described above.

JOHN KIRKPATRICK

Digitally signed by JOHN KIRKPATRICK
Date: 2024.12.20 15:40:56 -05'00'

Signature

Date